SCHEMBL3316121

SCHEMBL3316121

O=c1[nH]ccc2cc(NC3CN(CC4CCCCC4)C3)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 9/20 0.43
MAP2K1 Q02750 1/20 0.42
IP6K1 Q92551 1/20 0.41
ROCK1 Q13464 5/20 0.39
PRKACA P17612 4/20 0.39
PRKACG P22612 3/20 0.39
PRKACB P22694 3/20 0.39
KIT P10721 1/20 0.38
FLT3 P36888 1/20 0.38
ACHE P22303 1/20 0.37
HTR4 Q13639 1/20 0.37
PRKCD Q05655 1/20 0.37
PRKG1 Q13976 1/20 0.37
PKN1 Q16512 1/20 0.37
PKN2 Q16513 1/20 0.37
AAK1 Q2M2I8 1/20 0.37
CDC42BPA Q5VT25 1/20 0.37
Q6ZSR9 Q6ZSR9 1/20 0.37
BMP2K Q9NSY1 1/20 0.37
CDC42BPB Q9Y5S2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3317132 0.94 ROCK1 (0.42) ROCK2MAP2K1ROCK1PRKACAPRKACG
SCHEMBL3311535 0.93 PRKACA (0.41) ROCK2MAP2K1IP6K1ROCK1PRKACA
SCHEMBL3311544 0.93 PRKACA (0.41) ROCK2MAP2K1IP6K1ROCK1PRKACA
SCHEMBL3316992 0.92 ROCK2 (0.46) ROCK2IP6K1ROCK1
SCHEMBL3316985 0.92 ROCK2 (0.46) ROCK2IP6K1ROCK1
SCHEMBL3315491 0.87 ROCK2 (0.47) ROCK2ROCK1
SCHEMBL3315481 0.87 ROCK2 (0.47) ROCK2ROCK1
SCHEMBL3315424 0.87 PRKACA (0.43) ROCK2MAP2K1ROCK1PRKACAPRKACG
SCHEMBL3315430 0.87 PRKACA (0.43) ROCK2MAP2K1ROCK1PRKACAPRKACG
SCHEMBL3311595 0.83 IP6K1 (0.44) ROCK2IP6K1ROCK1PRKACAKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
EP-2114920-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES Sanofi-Aventis (FR) 2009-11-11 EP disclosed
WO-2008077552-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives MYLK2, MYLK, MYLK3 ROCK2 6/4885MAP2K1 1431/4885IP6K1 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.